Interventions for leg edema and varicosities in pregnancy. What evidence?

A. A. Bamigboye,G. Hofmeyr

DOI: https://doi.org/10.1016/J.EJOGRB.2006.03.008

2006-11-01

Abstract:

What problem does this paper attempt to address?

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Shuyuan Chen,Raul A Bastarrachea,Brad J Roberts,V Saroja Voruganti,Patrice A Frost,Edna J Nava-Gonzalez,Hector E Arriaga-Cazares,Jiaxi Chen,Pintong Huang,Ralph A DeFronzo,Anthony G Comuzzie,Paul A Grayburn

DOI: https://doi.org/10.4161/cc.27997

2014-01-01

Abstract:Both major forms of diabetes mellitus (DM) involve β-cell destruction and dysfunction. New treatment strategies have focused on replenishing the deficiency of β-cell mass common to both major forms of diabetes by islet transplantation or β-cell regeneration. The pancreas, not the liver, is the ideal organ for islet regeneration, because it is the natural milieu for islets. Since islet mass is known to increase during obesity and pregnancy, the concept of stimulating pancreatic islet regeneration in vivo is both rational and physiologic. This paper proposes a novel approach in which non-viral gene therapy is targeted to pancreatic islets using ultrasound targeted microbubble destruction (UTMD) in a non-human primate model (NHP), the baboon. Treated baboons received a gene cocktail comprised of cyclinD2, CDK, and GLP1, which in rats results in robust and durable islet regeneration with normalization of blood glucose, insulin, and C-peptide levels. We were able to generate important preliminary data indicating that gene therapy by UTMD can achieve in vivo normalization of the intravenous (IV) glucose tolerance test (IVGTT) curves in STZ hyperglycemic-induced conscious tethered baboons. Immunohistochemistry clearly demonstrated evidence of islet regeneration and restoration of β-cell mass.
Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Shuyuan Chen,Raúl A. Bastarrachea,Brad J. Roberts,V. Saroja Voruganti,Patrice A. Frost,Edna J. Nava‐González,Héctor Eliud Arriaga-Cázares,Jiaxi Chen,Pintong Huang,Ralph A. DeFronzo,Anthony G. Comuzzie,Paul Grayburn

DOI: https://doi.org/10.4161/cc.27997

2014-01-01

Abstract:Both major forms of diabetes mellitus (DM) involve β-cell destruction and dysfunction. New treatment strategies have focused on replenishing the deficiency of β-cell mass common to both major forms of diabetes by islet transplantation or β-cell regeneration. The pancreas, not the liver, is the ideal organ for islet regeneration, because it is the natural milieu for islets. Since islet mass is known to increase during obesity and pregnancy, the concept of stimulating pancreatic islet regeneration in vivo is both rational and physiologic. This paper proposes a novel approach in which non-viral gene therapy is targeted to pancreatic islets using ultrasound targeted microbubble destruction (UTMD) in a non-human primate model (NHP), the baboon. Treated baboons received a gene cocktail comprised of cyclinD2, CDK, and GLP1, which in rats results in robust and durable islet regeneration with normalization of blood glucose, insulin, and C-peptide levels. We were able to generate important preliminary data indicating that gene therapy by UTMD can achieve in vivo normalization of the intravenous (IV) glucose tolerance test (IVGTT) curves in STZ hyperglycemic-induced conscious tethered baboons. Immunohistochemistry clearly demonstrated evidence of islet regeneration and restoration of β-cell mass.
In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Jing-Yu Lin,Jie Cheng,Ya-Qin Du,Wei Pan,Zhong Zhang,Jin Wang,Jie An,Fan Yang,Yun-Fei Xu,Hui Lin,Wen-Tao An,Jia Wang,Zhao Yang,Ren-Jie Chai,Xue-Ying Sha,Hui-Li Hu,Jin-Peng Sun,Xiao Yu

DOI: https://doi.org/10.1038/s41421-020-0159-x

IF: 38.079

2020-01-01

Cell Discovery

Abstract:Tissue regeneration, such as pancreatic islet tissue propagation in vitro, could serve as a promising strategy for diabetes therapy and personalised drug testing. However, such a strategy has not been realised yet. Propagation could be divided into two steps, in vitro expansion and repeated passaging. Even the first step of the in vitro islet expansion has not been achieved to date. Here, we describe a method that enables the expansion of islet clusters isolated from pregnant mice or wild-type rats by employing a combination of specific regeneration factors and chemical compounds in vitro. The expanded islet clusters expressed insulin, glucagon and somatostatin, which are markers corresponding to pancreatic β cells, α cells and δ cells, respectively. These different types of cells grouped together, were spatially organised and functioned similarly to primary islets. Further mechanistic analysis revealed that forskolin in our recipe contributed to renewal and regeneration, whereas exendin-4 was essential for preserving islet cell identity. Our results provide a novel method for the in vitro expansion of islet clusters, which is an important step forward in developing future protocols and media used for islet tissue propagation in vitro. Such method is important for future regenerative diabetes therapies and personalised medicines using large amounts of pancreatic islets derived from the same person.
Improvement effects of transplanting pancreatic islet that previously incubated with biomaterials on the diabetic nephropathy in STZ- diabetic rats

DOI: https://doi.org/10.1186/s12882-024-03572-4

2024-05-10

BMC Nephrology

Abstract:Islet transplantation is an effective treatment for diabetes or even its complications. Aim of this study is to investigate efficacy of biomaterial treated islet transplantation on treating diabetic nephropathy.

urology & nephrology
Listening to Teachers

E. Scott

DOI: https://doi.org/10.1007/s12052-010-0218-0

2010-04-07

Abstract:
Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes

Boyang Qi,Yang Ding,Ying Zhang,Longfa Kou,Ying-Zheng Zhao,Qing Yao

DOI: https://doi.org/10.1039/d3bm01295f

2024-01-04

Biomaterials Science

Abstract:Islet transplantation holds significant promise as a curative approach for type 1 diabetes (T1D). However, the transition of islet transplantation from the experimental phase to widespread clinical implementation has not occurred yet. One major hurdle in this field is the challenge of insufficient vascularization and subsequent early loss of transplanted islets, especially in non-intraportal transplantation sites. The establishment of a fully functional vascular system following transplantation is crucial for the survival and secretion function of islet grafts. This vascular network not only ensures the delivery of oxygen and nutrients, but also plays a critical role in insulin release and the timely removal of metabolic waste from the grafts. This review summarizes recent advances in effective strategies to improve graft revascularization and enhance islet survival. These advancements include the local release and regulation of angiogenic factors ( e.g. , vascular endothelial growth factor, VEGF), co-transplantation of vascular fragments, and pre-vascularization of the graft site. These innovative approaches pave the way for the development of effective islet transplantation therapies for individuals with T1D.

materials science, biomaterials
Effect of Thioketal Antioxidants on Islet Cell Transplantation

Shammy Raj,Kosala D. Waduthanthri,Purushothaman Kuppan,Gregory S. Korbutt,Larry D. Unsworth,Andrew R. Pepper

DOI: https://doi.org/10.1002/adtp.202200132

IF: 5.003

2022-10-28

Advanced Therapeutics

Abstract:Pancreatic islet transplantation is an effective strategy for restoring glucose regulation for highly selected patients with type 1 diabetes. However, an undesirable level of islet cell death is caused by oxidative stress that occurs during islet isolation, culture, and transplantation. The loss of islets throughout the transplantation procedure often necessitates multiple human donors per recipient to achieve insulin independence. Administration of exogenous antioxidants has shown promise in both preserving islet cell viability and functionality post‐transplantation. Herein, thioketal (TK) antioxidant is evaluated using neonatal porcine islets and Beta‐TC‐6 cells exposed to H2O2 for changes in membrane integrity, oxygen consumption rates, and lipid peroxidation. Diabetic BALB/c mice are transplanted with a marginal dose of syngeneic islets, ±48‐h TK pre‐treatment, under the kidney capsule. Graft function is measured by nonfasting blood glucose and glucose tolerance testing. It is found that 200 µM of TK was not cytotoxic, reduced reactive oxygen species‐mediated oxidative islet damage, preserved in vitro islet cell functionality, and facilitated superior murine syngeneic marginal islet mass engraftment. These results demonstrate that the antioxidant attributes of TK reduce the deleterious effects of reactive oxygen species experienced in vitro and enhance marginal islet mass transplant outcomes. Pancreatic islet transplantation is an effective treatment for restoring glucose regulation in type 1 diabetic patients. However, oxidative stress induced islet death that occurs during islet isolation, culture, and transplantation is still a major hurdle. This study demonstrates that the antioxidant property of Thioketal can reduce the deleterious effects of reactive oxygen species on islets and enhance transplant outcomes.
Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Kai Wang,Xi Wang,Cheng-sheng Han,Liang-yi Chen,Ying Luo

DOI: https://doi.org/10.3791/54995

2017-01-01

Journal of Visualized Experiments

Abstract:Islet transplantation has been clinically proven to be effective at treating type 1 diabetes. However, the current intrahepatic transplantation strategy may incur acute whole blood reactions and result in poor islet engraftment. Here, we report a robust protocol for the transplantation of islets at the extrahepatic transplantation site-the epididymal fat pad (EFP)-in a diabetic mouse model. A protocol to isolate and purify islets at high yields from C57BL/6J mice is described, as well as a transplantation method performed by seeding islets onto a decellularized scaffold (DCS) and implanting them at the EFP site in syngeneic C57BL/6J mice rendered diabetic by streptozotocin. The DCS graft containing 500 islets reversed the hyperglycemic condition within 10 days, while the free islets without DCS required at least 30 days. The normoglycemia was maintained for up to 3 months until the graft was explanted. In conclusion, DCS enhanced the engraftment of islets into the extrahepatic site of the EFP, which could easily be retrieved and might provide a reproducible and useful platform for investigating the scaffold materials, as well as other transplantation parameters required for a successful islet engraftment.
Immune-Protective Formulations and Process Strategies for Improved Survival and Function of Transplanted Islets

Yannan Shi,Ying-Zheng Zhao,Zhikai Jiang,Zeqing Wang,Qian Wang,Longfa Kou,Qing Yao

DOI: https://doi.org/10.3389/fimmu.2022.923241

IF: 7.3

2022-07-13

Frontiers in Immunology

Abstract:Type 1 diabetes (T1D) is an autoimmune disease caused by the immune system attacking and destroying insulin-producing β cells in the pancreas. Islet transplantation is becoming one of the most promising therapies for T1D patients. However, its clinical use is limited by substantial cell loss after islet infusion, closely related to immune reactions, including instant blood-mediated inflammatory responses, oxidative stress, and direct autoimmune attack. Especially the grafted islets are not only exposed to allogeneic immune rejection after transplantation but are also subjected to an autoimmune process that caused the original disease. Due to the development and convergence of expertise in biomaterials, nanotechnology, and immunology, protective strategies are being investigated to address this issue, including exploring novel immune protective agents, encapsulating islets with biomaterials, and searching for alternative implantation sites, or co-transplantation with functional cells. These methods have significantly increased the survival rate and function of the transplanted islets. However, most studies are still limited to animal experiments and need further studies. In this review, we introduced the immunological challenges for islet graft and summarized the recent developments in immune-protective strategies to improve the outcomes of islet transplantation.

immunology
Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

Beatrice Xuan Ho,Adrian Kee Keong Teo,Natasha Hui Jin Ng

DOI: https://doi.org/10.3389/fimmu.2024.1375177

IF: 7.3

2024-04-08

Frontiers in Immunology

Abstract:Human allogeneic pancreatic islet transplantation is a life-changing treatment for patients with severe Type 1 Diabetes (T1D) who suffer from hypoglycemia unawareness and high risk of severe hypoglycemia. However, intensive immunosuppression is required to prevent immune rejection of the graft, that may in turn lead to undesirable side effects such as toxicity to the islet cells, kidney toxicity, occurrence of opportunistic infections, and malignancies. The shortage of cadaveric human islet donors further limits islet transplantation as a treatment option for widespread adoption. Alternatively, porcine islets have been considered as another source of insulin-secreting cells for transplantation in T1D patients, though xeno-transplants raise concerns over the risk of endogenous retrovirus transmission and immunological incompatibility. As a result, technological advancements have been made to protect transplanted islets from immune rejection and inflammation, ideally in the absence of chronic immunosuppression, to improve the outcomes and accessibility of allogeneic islet cell replacement therapies. These include the use of microencapsulation or macroencapsulation devices designed to provide an immunoprotective environment using a cell-impermeable layer, preventing immune cell attack of the transplanted cells. Other up and coming advancements are based on the use of stem cells as the starting source material for generating islet cells 'on-demand'. These starting stem cell sources include human induced pluripotent stem cells (hiPSCs) that have been genetically engineered to avoid the host immune response, curated HLA-selected donor hiPSCs that can be matched with recipients within a given population, and multipotent stem cells with natural immune privilege properties. These strategies are developed to provide an immune-evasive cell resource for allogeneic cell therapy. This review will summarize the immunological challenges facing islet transplantation and highlight recent bio-engineering and cell-based approaches aimed at avoiding immune rejection, to improve the accessibility of islet cell therapy and enhance treatment outcomes. Better understanding of the different approaches and their limitations can guide future research endeavors towards developing more comprehensive and targeted strategies for creating a more tolerogenic microenvironment, and improve the effectiveness and sustainability of islet transplantation to benefit more patients.

immunology
Improvement of islet transplantation by the fusion of islet cells with functional blood vessels

Lisa Nalbach,Leticia P Roma,Beate M Schmitt,Vivien Becker,Christina Körbel,Selina Wrublewsky,Mandy Pack,Thomas Später,Wolfgang Metzger,Maximilian M Menger,Florian S Frueh,Claudia Götz,Haopeng Lin,Jocelyn E Manning Fox,Patrick E MacDonald,Michael D Menger,Matthias W Laschke,Emmanuel Ampofo

DOI: https://doi.org/10.15252/emmm.202012616

2020-11-02

EMBO Molecular Medicine

Abstract:<p>Pancreatic islet transplantation still represents a promising therapeutic strategy for curative treatment of type 1 diabetes mellitus. However, a limited number of organ donors and insufficient vascularization with islet engraftment failure restrict the successful transfer of this approach into clinical practice. To overcome these problems, we herein introduce a novel strategy for the generation of prevascularized islet organoids by the fusion of pancreatic islet cells with functional native microvessels. These insulin‐secreting organoids exhibit a significantly higher angiogenic activity compared to freshly isolated islets, cultured islets, and non‐prevascularized islet organoids. This is caused by paracrine signaling between the β‐cells and the microvessels, mediated by insulin binding to its corresponding receptor on endothelial cells. <i>In vivo</i>, the prevascularized islet organoids are rapidly blood‐perfused after transplantation by the interconnection of their autochthonous microvasculature with surrounding blood vessels. As a consequence, a lower number of islet grafts are required to restore normoglycemia in diabetic mice. Thus, prevascularized islet organoids may be used to improve the success rates of clinical islet transplantation.</p>

medicine, research & experimental
Some aspects of standardising performance characteristics for modular data acquisition systems

V. Haasz,H. Schumny

DOI: https://doi.org/10.1016/S0920-5489(02)00078-8

2003-03-01

Abstract:
1729-P: Role of ß-Cell Senescence in Islet Transplantation

KANAKO IWASAKI,PRISCILA CARAPETO,CRISTINA AGUAYO-MAZZUCATO

DOI: https://doi.org/10.2337/db23-1729-p

IF: 7.7

2023-06-20

Diabetes

Abstract:Islet transplantation (Tx) is an effective intervention to prevent severe hypoglycemia and provide insulin independence in type 1 diabetes (T1D). Previous studies have shown that islets from older donors are less effective in reversing blood glucose (BG) than those of younger ones. Cellular senescence leads to age-related β-cell dysfunction and drives alloimmune responses to organs from older donors, but can be targeted with senolysis. However, the mechanism of pancreatic β-cell senescence in transplant grafts and its pathological significance are unknown. Therefore, we performed two types of islet Tx to test the hypothesis that cellular senescence may play a role in loss of graft functionality/viability and that the use of senolysis may ameliorate it: 1) overnight cultured 600 IEQ islets from normoglycemic rats were transplanted into kidney capsule of streptozotocin-induced diabetic immunodeficient mice (Stz-Ms). After 2 weeks, the grafts were removed and compared with the cultured islets (control). In Stz-Ms, the nuclear exclusion rate of Hmgb1 and p21-positive cells tended to increase, and the mRNA levels of p16, Il-6, and β-cells related genes were significantly higher than in control islets indicating β-cell senescence after transplantation. To test if the elimination of p16 positive senescent β-cells from transplanted islets improved BG levels, 2) 440 IEQ islets from INK-ATTAC mice (p16Ink4a mediated apoptosis through targeted activation of caspase) were transplanted into Stz-Ms and treated intraperitoneally with BB Homodimerizer (BB) or vehicle for 2 terms of 3 consecutive days, of which 2 weeks of rest. With senolysis, there was a decrease in fed glucose levels and p16 mRNA expression while expression of hallmark β-cell genes increased by 74%, which correlates with improved response to high glucose. In conclusion, islet transplantation increases β-cell senescence in grafts and senolysis improves β-cell function. This has important implications in increasing graft function and survival in the treatment of T1D. Disclosure K.Iwasaki: None. P.Carapeto: None. C.Aguayo-mazzucato: None. Funding Manpei Suzuki Diabetes Foundation

endocrinology & metabolism
Reversal of Early Diabetic Nephropathy by Islet Transplantation under the Kidney Capsule in a Rat Model

Yunqiang He,Ziqiang Xu,Mingshi Zhou,Minmin Wu,Xuehai Chen,Silu Wang,Kaiyan Qiu,Yong Cai,Hongxing Fu,Bicheng Chen,Mengtao Zhou

DOI: https://doi.org/10.1155/2016/4157313

IF: 4.0608

2016-01-01

Journal of Diabetes Research

Abstract:Objective . Diabetic nephropathy (DN) is a common microvascular complication of diabetes mellitus, and insulin therapy has many side effects in the treatment of DN. Islet transplantation has emerged as a promising therapy for diabetic patients. This study was established to investigate its advantageous effects in a rat model of early DN. Methods . Streptozotocin was administered to the rats to induce diabetes. Twelve weeks later, the diabetic rats were divided into 3 groups: the islet-transplanted group (IT group), the insulin-treated group (IN group), and the untreated group (DN group). Renal injury and kidney structure were assessed by urinalysis and transmission electron microscopy (TEM) detection. Immunohistochemical staining and western blotting were performed to assess renal fibrosis levels. Results . The early DN features were reversed and the glomerular filtration barrier and basement membrane structures were improved at 4 weeks after islet transplantation. The urine microalbumin-to-creatinine ratio (ACR), protein-to-creatinine ratio, and mean thickness of the glomerular basement membrane (GBM) were significantly decreased in the IT group. The expression of renal fibrotic factors was also significantly decreased. Conclusions . These data suggest that early DN can be reversed after islet transplantation, and they may facilitate the development of a clinical therapeutic strategy for human diabetes mellitus.

endocrinology & metabolism,medicine, research & experimental
Islet isolation for allotransplantation: variables associated with successful islet yield and graft function

R. Nano,B. Clissi,R. Melzi,G. Calori,P. Maffi,B. Antonioli,S. Marzorati,L. Aldrighetti,M. Freschi,T. Grochowiecki,C. Socci,A. Secchi,V. Di Carlo,E. Bonifacio,F. Bertuzzi

DOI: https://doi.org/10.1007/s00125-005-1725-3

IF: 8.2

2005-04-14

Diabetologia

Abstract:Aims/hypothesisEfficient islet isolation is an important prerequisite for successful clinical islet transplantation. Although progressively improved, islet yield and quality are, however, unpredictable and variable and require standardisation.MethodsSince 1989 we have processed 437 pancreases using the automated method. The donor characteristics, pancreas procurement, and digestion and purification procedures including a wide enzyme characterisation of these pancreases were analysed and correlated with islet yield and transplant outcome.ResultsBy univariate analysis, islet yield was significantly associated with donor age (r=0.16; p=0.0009), BMI (r=0.19; p=0.0004), good pancreas condition (p=0.0031) and weight (r=0.15; p=0.0056), total collagenase activity (r=0.22; p=0.0001), adjusted collagenase activity/mg (r=0.18; p=0.0002), collagenase activity/solution volume (r=0.18; p=0.0002) and neutral protease activity/solution volume (r=0.14; p=0.0029). A statistically significant contribution to the variability of islet yield in a multivariate analysis performed on donor variables was found for donor BMI (p=0.0008). In a multivariate analysis performed on pancreas variables a contribution was found for pancreas weight (p=0.0064), and for a multivariate analysis performed on digestion variables we found a contribution for digestion time (p=0.0048) and total collagenase activity (p=0.0001). Twenty-four patients with type 1 diabetes received single islet preparations from single donors. In these patients, multivariate analyses showed that the reduction in insulin requirement was significantly associated with morphological aspects of islets (p=0.0010) and that 1-month C-peptide values were associated with islet purity (p=0.0071).Conclusions/interpretationThese data provide baseline donor, digestion and purification selection criteria for islet isolation using the automated method and indicate that the morphological aspect may be a clinically relevant measure of islets on which the decision for transplant can be based.

endocrinology & metabolism
Advances in Encapsulation and Delivery Strategies for Islet Transplantation

Siying Wu,Liying Wang,Yifen Fang,Hai Huang,Xinru You,Jun Wu

DOI: https://doi.org/10.1002/adhm.202100965

IF: 10

2021-09-03

Advanced Healthcare Materials

Abstract:Type 1 diabetes mellitus (T1DM) is a chronic metabolic disease caused by the destruction of pancreatic β-cells in response to autoimmune reactions. Shapiro et al. conducted novel islet transplantation with a glucocorticoid-free immunosuppressive agent in 2000 and achieved great success; since then, islet transplantation has been increasingly regarded as a promising strategy for the curative treatment of T1DM. However, many unavoidable challenges, such as a lack of donors, poor revascularization, blood-mediated inflammatory reactions, hypoxia, and side effects caused by immunosuppression have severely hindered the widespread application of islet transplantation in clinics. Biomaterial-based encapsulation and delivery strategies are proposed for overcoming these obstacles, and have demonstrated remarkable improvements in islet transplantation outcomes. Herein, the major problems faced by islet transplantation are summarized and updated biomaterial-based strategies for islet transplantation, including islet encapsulation across different scales, delivery of stem cell-derived beta cells, co-delivery of islets with accessory cells and immunomodulatory molecules are highlighted.

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions

Xinyu Li,Qiang Meng,Lei Zhang

DOI: https://doi.org/10.1155/2018/2424586

IF: 4.4929

2018-09-23

Journal of Immunology Research

Abstract:Pancreatic islet transplantation as a therapeutic option for type 1 diabetes mellitus is gaining widespread attention because this approach can restore physiological insulin secretion, minimize the risk of hypoglycemic unawareness, and reduce the risk of death due to severe hypoglycemia. However, there are many obstacles contributing to the early mass loss of the islets and progressive islet loss in the late stages of clinical islet transplantation, including hypoxia injury, instant blood-mediated inflammatory reactions, inflammatory cytokines, immune rejection, metabolic exhaustion, and immunosuppression-related toxicity that is detrimental to the islet allograft. Here, we discuss the fate of intrahepatic islets infused through the portal vein and propose potential interventions to promote islet allograft survival and improve long-term graft function.

immunology
Bone Marrow-Derived Mesenchymal Stem Cells Improve Rat Islet Graft Revascularization by Upregulating ISL1

Ying Wang,Jing‐Wen Wang,Yang Li,Xiao‐Hui Tian,Xin‐Shun Feng,Shu‐Cong Zhang,Pei‐Jun Liu,Wu‐Jun Xue,Jin Zheng,Xiao‐Ming Ding,Jing-Wen Wang,Xiao-Hui Tian,Xin-Shun Feng,Shu-Cong Zhang,Pei-Jun Liu,Wu-Jun Xue,Xiao-Ming Ding

DOI: https://doi.org/10.1002/stem.3378

IF: 5.845

2021-04-03

Stem Cells

Abstract:Abstract Revascularization of the islet transplant is a crucial step that defines the success rate of patient recovery. Bone marrow-derived mesenchymal stem cells (BMSCs) have been reported to promote revascularization; however, the underlying cellular mechanism remains unclear. Moreover, our liquid chromatography-tandem mass spectrometry results showed that BMSCs could promote the expression of insulin gene enhancer binding protein-1 (ISL1) in islets. ISL1 is involved in islets proliferation and plays a potential regulatory role in the revascularization of islets. This study identifies the ISL1 protein as a potential modulator in BMSCs-mediated revascularization of islet grafts. We demonstrated that the survival rate and insulin secretion of islets were increased in the presence of BMSCs, indicating that BMSCs promote islet revascularization in a coculture system and rat diabetes model. Interestingly, we also observed that the presence of BMSCs led to an increase in ISL1 and vascular endothelial growth factor A (VEGFA) expression in both islets and the INS-1 rat insulinoma cell line. In silico protein structure modeling indicated that ISL1 is a transcription factor that has four binding sites with VEGFA mRNA. Further results showed that overexpression of ISL1 increased both the abundance of VEGFA transcripts and protein accumulation, while inhibition of ISL1 decreased the abundance of VEGFA. Using a ChIP-qPCR assay, we demonstrated that direct molecular interactions between ISL1 and VEGFA occur in INS-1 cells. Together, these findings reveal that BMSCs promote the expression of ISL1 in islets and lead to an increase in VEGFA in islet grafts. Hence, ISL1 is a potential target to induce early revascularization in islet transplantation.

oncology,cell biology,hematology,biotechnology & applied microbiology,cell & tissue engineering
Transplantation of rat pancreatic islets vitrified-warmed on the nylon mesh device and the silk fibroin sponge disc

Kenyu Nakayama-Iwatsuki,Takahiro Yamanaka,Jun Negishi,Junki Teshima,Yasushi Tamada,Masumi Hirabayashi,Shinichi Hochi

DOI: https://doi.org/10.1080/19382014.2020.1849928

2020-11-01

Islets

Abstract:We report the adaptability of rat islets vitrified-warmed on nylon mesh (NM) device or silk fibroin (SF) sponge disc for the normalization of the blood glucose level in rat models of diabetes. One-hundred rat islets were cryopreserved according to a minimum volume cooling protocol on an NM device or a solid surface vitrification protocol on an SF sponge disc. The recovery rate (97.1% vs. 93.8%), the viability (77.9% vs. 74.4%), and the stimulation index (4.7 vs. 4.2) in glucose-stimulated insulin secretion (GSIS) assay of the post-warm islets were comparable between the NM vitrification and the SF vitrification groups. The viability and the stimulation index of the fresh control islets were identified to be 97.5% and 6.5, respectively. Eight hundred islets from the NM or the SF vitrification group or the fresh control group were transplanted beneath the kidney capsule of a streptozotocin-induced diabetic rat (blood glucose level > 350 mg/dl). Within 3 weeks after transplantation, the acquisition of euglycemia (< 200 mg/dl) was observed in recipient rats (80.0–83.3%). An intraperitoneal glucose tolerance test on Day-30 and Day-60 showed similar 2-h responses to the glucose uptake of cured rats among the compared groups. Moreover, the successful engraftment of transplants was confirmed by the Day-70 nephrectomy through the subsequent diabetes reversal and histological evaluation. Thus, large quantities of rat islets vitrified-warmed on an NM device or an SF sponge disc were proven to be fully functional both in vitro and in vivo, due to the GSIS and syngeneic transplantation, respectively.
Biomimetic Artificial Islet Model with Vascularized Microcapsule Structures for Durable Glycemic Control

Jingbo Li,Yile Fang,Zhuhao Wu,Luoran Shang,Ling Li

DOI: https://doi.org/10.1088/2752-5724/ad47ce

2024-01-01

Materials Futures

Abstract:Islet transplantation is a promising strategy for diabetes mellitus treatment as it can recapitulate endogenous insulin secretion and provide long-term glycemic control. Islet models constructed in biomaterial scaffolds that reproduce biological characteristics of native islets is a feasible option to circumvent the dilemma of donor shortage and the requirement of chronic immunosuppression. Herein, we developed bioinspired artificial microcapsule-based islet models with microvessels for glycemic control using microfluidic electrospray strategy. Microfluidic electrospray can generate uniform hydrogel microcapsules with core-shell structure for encapsulating islet cells. The cell-laden microcapsules enabled the efficient transportation of nutrient, oxygen, and insulin; as well as the incorporation with microvessels for prompting glucose responsiveness and molecular exchange. We demonstrated by in vivo experiments that the blood glucose, food intake, and body weight of diabetic mouse models were alleviated, and the glucose tolerance was promoted after the engraftment of islet microcapsules. We further demonstrated the improved functionality of transplanted islet model in insulin secretion, immune escape, and microcirculation using standard histological and molecular analysis. These results indicated that the microcapsules with microvessels are promising artificial islet models and are valuable for treating diabetes.

Interventions for leg edema and varicosities in pregnancy. What evidence?

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Improvement effects of transplanting pancreatic islet that previously incubated with biomaterials on the diabetic nephropathy in STZ- diabetic rats

Listening to Teachers

Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes

Effect of Thioketal Antioxidants on Islet Cell Transplantation

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Immune-Protective Formulations and Process Strategies for Improved Survival and Function of Transplanted Islets

Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

Improvement of islet transplantation by the fusion of islet cells with functional blood vessels

Some aspects of standardising performance characteristics for modular data acquisition systems

1729-P: Role of ß-Cell Senescence in Islet Transplantation

Reversal of Early Diabetic Nephropathy by Islet Transplantation under the Kidney Capsule in a Rat Model

Islet isolation for allotransplantation: variables associated with successful islet yield and graft function

Advances in Encapsulation and Delivery Strategies for Islet Transplantation

The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions

Bone Marrow-Derived Mesenchymal Stem Cells Improve Rat Islet Graft Revascularization by Upregulating ISL1

Transplantation of rat pancreatic islets vitrified-warmed on the nylon mesh device and the silk fibroin sponge disc

Biomimetic Artificial Islet Model with Vascularized Microcapsule Structures for Durable Glycemic Control